Author Archives: admin


North Island College alum on cutting edge of bio-medical research – Comox Valley Record

NIC alumna Milena Restan bioprints on a BioX printer at the Willerth Laboratory in Victoria. photo supplied

North Island College alum Milena Restan is combining her love of medicine and engineering in ground-breaking stem cell and tissue engineering research to help patients.

Restan has completed a biomedical engineering degree at the University of Victoria and was recently the lead author of a research paper on 3D bioprinting stem cell-derived neural tissue.

It was very special to be a lead author as an undergrad student, said Restan.

Originally from the Comox Valley, Restan began her engineering journey at NIC but was always torn between medicine and engineering.

I always wanted to be a doctor, but after taking a calculus course I was really torn between pursuing my love of mathematics and medicine, she said. When I learned about NICs engineering transfer with UVic, and about the option of biomedical engineering, I realized I didnt have to choose it was the perfect combination.

Biomedical engineering focuses on mechanical and electrical engineering, combined with anatomy, physiology and biochemistry.

Engineering is learning about why things work the way they do, and then using that knowledge to solve all kinds of real-world problems, said Dennis Lightfoot, NIC engineering instructor. Todays engineering students are going to be preparing to solve the problems of the present and the future including mitigating climate change, designing for sustainability, and developing new renewable energy sources for the future. Biomedical research and development like Milena is working on will also be a growth area for our future engineers.

NIC students can seamlessly transfer directly to UVic thanks to a partnership agreement between the two institutions one of many partnership and transfer agreements NIC has with institutions across B.C., Canada and internationally.

Our goal is to make it as easy as possible for students to complete their first year at NIC and then move on to the institution of their choice to continue their studies, said Neil Cruickshank, dean of arts, science, technology, business and applied studies.

It was after her transfer to UVic that Restans career path turned again. Her original focus was on medical device design and prosthetics when she was introduced to 3D tissue printing. She then got a job working with Willerth Lab, run by Dr. Stephanie Willerth at the University of Victoria, which specialized in tissue engineering and regenerative medicine.

You can take a mature cell, reprogram it back to a pluripotent stem cell and 3D bioprint it along with various biomaterials, she explained. This allows us to engineer personalized tissue models which can be used to study disease progression. Right now, were focusing on neural tissues, but were hoping to expand to cardiac tissues. Theres a lot of potential with this approach.

Restan is wrapping up her final year at UVic and looking forward to graduation in June. For now, Restan is looking forward to furthering her research work and is also considering pursuing her MD/PhD, which combines clinical medical training with research.

What Ive learned through all this is that you never know what opportunities may present themselves. My advice to students would be to take electives youre interested in and to look for opportunities to volunteer outside the classroom. You never know what pathways will open up for you.

CourtenayNorth Island College

View post:
North Island College alum on cutting edge of bio-medical research - Comox Valley Record

Cell Separation Technology Market Size, Scope and Forecast | Beckman Coulter, Becton, Dickinson and Company, GE Healthcare, Merck KGaA, Miltenyi…

New Jersey, United States This Cell Separation Technology Market research examines the state and future prospects of the Cell Separation Technology market from the perspectives of competitors, regions, products, and end Applications/industries. The Worldwide Cell Separation Technology market is segmented by product and Application/end industries in this analysis, which also analyses the different players in the global and key regions.

The analysis for the Cell Separation Technology market is included in this report in its entirety. The in-depth secondary research, primary interviews, and internal expert reviews went into the Cell Separation Technology reports market estimates. These market estimates were taken into account by researching the effects of different social, political, and economic aspects, as well as the present market dynamics, on the growth of the Cell Separation Technology market.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @https://www.verifiedmarketresearch.com/download-sample/?rid=39900

Key Players Mentioned in the Cell Separation Technology Market Research Report:

Beckman Coulter, Becton, Dickinson and Company, GE Healthcare, Merck KGaA, Miltenyi Biotec, BD Bioscience, Thermo Fisher Scientific, Stemcell Technologies, and many others.

The Porters Five Forces analysis, which explains the five forces: customers bargaining power, distributors bargaining power, the threat of substitute products, and degree of competition in the Cell Separation Technology Market, is included in the report along with the market overview, which includes the market dynamics. It describes the different players who make up the market ecosystem, including system integrators, middlemen, and end-users. The competitive environment of the Cell Separation Technology marketis another major topic of the report. For enhanced decision-making, the research also provides in-depth details regarding the COVID-19 scenario and its influence on the market.

Cell Separation TechnologyMarket Segmentation:

Cell Separation Technology Market, By Type

Density Gradient Centrifugation Immunodensity Cell Separation Microfluidic Cell Separation Immunomagnetic Cell Separation Fluorescence-activated Cell Sorting (FACS) Others

Cell Separation Technology Market, By Application

Stem Cell Research Immunology Neuroscience Cancer Research Others

Inquire for a Discount on this Premium Report@ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=39900

Cell Separation Technology Market Report Scope

Key questions answered in the report:

1. Which are the five top players of the Cell Separation Technology market?

2. How will the Cell Separation Technology market change in the next five years?

3. Which product and application will take a lions share of the Cell Separation Technology market?

4. What are the drivers and restraints of the Cell Separation Technology market?

5. Which regional market will show the highest growth?

6. What will be the CAGR and size of the Cell Separation Technology market throughout the forecast period?

For More Information or Query or Customization Before Buying, Visit @ https://www.verifiedmarketresearch.com/product/cell-separation-technology-market/

Visualize Cell Separation Technology Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

Visualize Cell Separation Technology Market using VMI @ https://www.verifiedmarketresearch.com/vmintelligence/

About Us: Verified Market Research

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research, assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080 UK: +44 (753)-715-0008 APAC: +61 (488)-85-9400 US Toll-Free: +1 (800)-782-1768

Email: sales@verifiedmarketresearch.com

Website:- https://www.verifiedmarketresearch.com/

See the original post:
Cell Separation Technology Market Size, Scope and Forecast | Beckman Coulter, Becton, Dickinson and Company, GE Healthcare, Merck KGaA, Miltenyi...

What was the value of the Canine Stem Cell Therapy market in Europe in 2022? Indian Defence News – Indian Defence News

Canine Stem Cell Therapy Market Report Coverage: Key Growth Factors & Challenges, Segmentation & Regional Outlook, Top Industry Trends & Opportunities, Competition Analysis, COVID-19 Impact Analysis & Projected Recovery, and Market Sizing & Forecast.

Latest launched research on Global Canine Stem Cell Therapy Market, it provides detailed analysis with presentable graphs, charts and tables. This report covers an in depth study of the Canine Stem Cell Therapy Market size, growth, and share, trends, consumption, segments, application and Forecast 2030. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Canine Stem Cell Therapy Market. This report has been prepared by experienced and knowledgeable market analysts and researchers. Each section of the research study is specially prepared to explore key aspects of the global Canine Stem Cell Therapy Market. Buyers of the report will have access to accurate PESTLE, SWOT and other types of analysis on the global Canine Stem Cell Therapy market. Moreover, it offers highly accurate estimations on the CAGR, market share, and market size of key regions and countries.

Major Key players profiled in the report include: Aratana Therapeutics, Okyanos, Magellan Stem Cells, Stem Cell Vet, VetStem Biopharma, Medrego, Regeneus Ltd, MediVet Biologic, Cell Therapy Sciences

Download Free Sample PDF including COVID19 Impact Analysis, full TOC, Tables and [emailprotected] https://marketstrides.com/request-sample/canine-stem-cell-therapy-market

Dont miss the trading opportunities on Canine Stem Cell Therapy Market. Talk to our analyst and gain key industry insights that will help your business grow as you create PDF sample reports.

Segmental Analysis: The report has classified the global Canine Stem Cell Therapy market into segments including product type and application. Every segment is evaluated based on share and growth rate. Besides, the analysts have studied the potential regions that may prove rewarding for the Canine Stem Cell Therapy manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, there by helping market players to gain deep insights into the overall Canine Stem Cell Therapy industry.

Market split by Type, can be divided into: Allogeneic Stem Cells, Autologous Stem Cells

Market split by Application, can be divided into: Veterinary Hospitals, Veterinary Clinics, Veterinary Research Institutes

Share your budget and Get Exclusive Discount @ https://marketstrides.com/check-discount/canine-stem-cell-therapy-market

The authors of the report have analyzed both developing and developed regions considered for the research and analysis of the global Canine Stem Cell Therapy market. The regional analysis section of the report provides an extensive research study on different regional and country-wise Canine Stem Cell Therapy industry to help players plan effective expansion strategies.

Regions Covered in the Global Canine Stem Cell Therapy Market: North America (U.S., Canada) Europe (U.K., Germany, France, Italy) Asia Pacific (China, India, Japan, Singapore, Malaysia) Latin America (Brazil, Mexico) Middle East & Africa (Kuwait, Saudi Arabia Egypt)

Years Considered to Estimate the Market Size: History Year: 2019-2020 Base Year: 2021 Estimated Year: 2022 Forecast Year: 2022-2030

What market dynamics does this report cover? The report shares key insights on:

Go here to see the original:
What was the value of the Canine Stem Cell Therapy market in Europe in 2022? Indian Defence News - Indian Defence News

Circulating Tumor Cells (CTC) Liquid Biopsy Market Provides in-depth analysis of the Industry, with Current Trends and Future forecast 2022-2029 …

Circulating Tumor Cells (CTC) Liquid Biopsy Market report is a comprehensive background analysis of the industry, which includes an assessment of the parental market. With the global market data provided in the reliable marketing report, it has become easy to gain global perspective for the international business. The market report also contains the drivers and restraints for the market that are derived from SWOT analysis, and also shows what all the recent developments, product launches, joint ventures, mergers and acquisitions by the several key players and brands that are driving the market are by systemic company profiles.

In the persuasive market report, the complete and crystal clear outline of the market is penned down which is useful for many businesses. With this business report not only an unskilled individual but also a professional can easily extrapolate the entire market within a few seconds. This business report is prepared using data sourced from in-house databases, secondary and primary research performed by a team of industry experts. An influential market research report can be explored in terms of breakdown of data by manufacturers, region, type and application, market status, market share, growth rate, future trends, market drivers, opportunities and challenges, emerging trends, risks and entry barriers, sales channels, and distributors.

Global circulating tumor cells (CTC) liquid biopsy market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 25.3% in the forecast period of 2022 to 2029 and is expected to reach USD 5,756.44 million by 2029 from USD 1,001.83 million in 2021. The high prevalence of chronic diseases and increasing R&D activities for its effective application is likely to be the major drivers which propel the demand of the market in the forecast period.

Download Exclusive Sample Report (350 Pages PDF with All Related Graphs & Charts) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-circulating-tumor-cells-ctc-liquid-biopsy-market

The major companies which are dealing in the global circulating tumor cells (CTC) liquid biopsy market are Eurofins Genomics ( a subsidiary of Eurofins Scientific), MDx Health, Guardant Health, IMMUCOR, Thermo Fisher Scientific, Inc., Menarini Silicon Biosystems, QIAGEN, Exact Sciences Corporation, Myriad Genetics, Inc., LungLife AI, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc. , Natera Inc., ExoDx ( a subsidiary of Bio-Techne Corporation), Biocept, Inc., F. Hoffman-La Roche Ltd. ,FOUNDATION MEDICINE, INC., Lucence Health, Inc., Inivata Ltd, Biolidics Limited, Vortex Biosciences among others.

Competitive Landscape and GlobalCirculating Tumor Cells (CTC) Liquid Biopsy Share Analysis

The circulating tumor cells (CTC) liquid biopsy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breath, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to the circulating tumor cells (CTC) liquid biopsy market.

For instance,

Collaboration, joint ventures, and other strategies by the market player is enhancing the company market in the circulating tumor cells (CTC) liquid biopsy market, which also provides the benefit for the organization to improve their offering for circulating tumor cells (CTC) liquid biopsy market.

The liquid biopsy is a non-invasive blood test which detects circulating tumor cells and tumor DNA fragments which are released into the blood from primary tumors and metastatic sites.It is a simple and precise alternative to surgical biopsy procedure, which allows surgeon to detect cancer at a very early stage.

The circulating tumor cells are a rare sub-set of cells which function as a seed of metastases. It is found in blood of patients who have developed solid tumors. The testing of circulating tumor cells allows the detection and quantification of tumor cells in the blood of cancer patients. The various types of biological phenotypes of circulating tumor cells (CTCs) exits includes stem cell-like or mixed, mesenchymal or epithelial. These phenotypes are present in blood in a very small quantity. Due to which, their detection needs a phase of isolation-enrichment. After that, a second phase of detection.

The growing demand of circulating tumor cells (CTC) liquid biopsy because of their efficacy, high prevalence of cancer are the major drivers propelling the demand for circulating tumor cells (CTC) liquid biopsy market in the forecast period. However, the unclear regulatory and reimbursement scenario, shortage of skilled personnel is restraining the circulating tumor cells (CTC) liquid biopsy market growth in the forecast period.

The global circulating tumor cells (CTC) liquid biopsy market report provides details of market share, new developments, and impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.

Global Circulating Tumor Cells (CTC) Liquid Biopsy Market Scope and Market Size

Global circulating tumor cells (CTC) liquid biopsy market is categorized into three notable segments which are based on technology, application and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Table of Contents:

For More Insights Get Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-circulating-tumor-cells-ctc-liquid-biopsy-market

Global Circulating Tumor Cells (CTC) Liquid Biopsy Market Country Level Analysis

The global circulating tumor cells (CTC) liquid biopsy market is analysed and market size information is provided by country, technology, application and end user.

The countries covered in the global circulating tumor cells (CTC) liquid biopsy market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Poland, Turkey, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Lithuania, rest of Europe in Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, rest of Asia-Pacific (APAC) in Asia-Pacific(APAC) Brazil, Argentina, Peru, rest of South America in South America, South Africa, Saudi Arabia, UAE, Israel, Egypt, Kuwait and rest of Middle East and Africa in Middle East and Africa (MEA).

The U.S. is dominating the global circulating tumor cells (CTC) liquid biopsy in the North American region due to rise in number of cancer patients and presence of major players in the market. Whereas, Germany is dominating the circulating tumor cells (CTC) liquid biopsy market in the European region due to presence of untapped opportunities in Germany and growing geriatric population in Germany. Additionally, China is dominating the circulating tumor cells (CTC) liquid biopsy maket in the Asia Pacific region due to increased awareness regarding the early diagnosis and treatment of diseases such as cancer and increasing healthcare expenditure which leads to improvement in diagnostic rate.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

The Technological Development along with Public-Private Funding are Creating Opportunities in the GlobalCirculating Tumor Cells (CTC) Liquid Biopsy Market

Global circulating tumor cells (CTC) liquid biopsy market also provides you with detailed market analysis for every country growth in particular industry with wound debridement device sales, impact of advancement in the market, changes in regulatory scenarios with their support for the circulating tumor cells (CTC) liquid biopsy market. The data is available for historic period 2011 to 2019.

Read More @ https://www.databridgemarketresearch.com/reports/global-circulating-tumor-cells-ctc-liquid-biopsy-market

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @Corporatesales@databridgemarketresearch.com

Read more:
Circulating Tumor Cells (CTC) Liquid Biopsy Market Provides in-depth analysis of the Industry, with Current Trends and Future forecast 2022-2029 ...

Global Human Embryonic Stem Cell Market to be Driven by the Rapid Technological Advancements in the Forecast Period of 2022-2027 Designer Women -…

The new report by Expert Market Research titled, GlobalHuman Embryonic Stem Cell MarketReport and Forecast 2022-2027, gives an in-depth analysis of the global human embryonic stem cell market, assessing the market based on its segments like applications and major regions. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analysing the market based on the SWOT and Porters Five Forces models.

Get a Free Sample Report with Table of Contents:

The key highlights of the report include:https://bit.ly/3A1uYjO

Market Overview (2017-2027)

Historical Market Size (2020): USD 0.7 billion Forecast CAGR (2022-2027): 10%

The human embryonic stem cell market is being driven by the thriving medical sector. The rising demand for embryonic stem cells can be attributed to the increasing prevalence of chronic diseases around the world owing to the rising adoption of unhealthy and sedentary lifestyle among the youth and middle-class population. The increased risk of premature death as a result of chronic diseases is a growing concern. Therefore, human embryonic stem cells are gaining popularity in the medical sector. Furthermore, the increase in research grants and private as well as public funding for the development of effective and safe stem cell therapy products is further aiding the market growth. The rising investments from key players towards enhancing human embryonic cell therapy is expected to aid the market growth in the forecast period. In post-COVID days, as the various sectors recover from the negative impacts of the pandemic, human embryonic stem cells are likely to witness a rise in demand.

Industry Definition and Major Segments

Human embryonic stem cells, also known as human embryonic stem cells are self-replicating cells derived from human fetal tissue or human embryos that develop into tissues and cells of 3 primary layers. Furthermore, human embryonic stem cells are pluripotent and are roughly 3-5 days old. It is highly versatile, as it may split into new stem cells and even transform into any type of cell in the human body, allowing it to regenerate or repair any diseased organ or tissue.

Read Full Report with Table of Contents: https://bit.ly/3bor4HA

The human embryonic stem cell market, on the basis of application, can be segmented into:

Regenerative Medicine Stem Cell Biology Research Tissue Engineering Toxicology Testing

The regional markets for human embryonic stem cell include:

North America Europe Asia Pacific Latin America Middle East and Africa

Among these, North America represents a significant share of the human embryonic stem cell market.

Market Trends

The rising population along with the rapidly evolving medical infrastructure of emerging economies like India and China is expected to provide an impetus to the human embryonic stem cell market. Furthermore, technological advancements and increasing research and development investments and initiatives are expected to generate opportunities in the market. Researchers and scientists are increasingly leaning toward the transformation of human embryonic stem cells into a number of mature cell types that represent various tissues and organs in the body, as embryonic cells provide unequalled data relating to a variety of disorders. The increasing efforts by the governments of various nations towards enhancing human embryonic stem cell therapy is likely to be another key trend bolstering the market growth in the forecast period.

Key Market Players

The major players in the market Astellas Pharma Inc, Stemcell Technologies Inc., Biotime INC, Thermo Fisher Scientific, Inc., among others. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The companys expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1,000 companies to small and medium-sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

See original here:
Global Human Embryonic Stem Cell Market to be Driven by the Rapid Technological Advancements in the Forecast Period of 2022-2027 Designer Women -...

The Origins of Our Blood May Not Be What We Thought – SciTechDaily

Clusters of the earliest hematopoietic cells being born in the walls of the umbilical artery of a mouse embryo. The cells colored in red represent embryonic multipotent progenitor cells (eMPPs). Credit: Sachin H. Patel/Boston Childrens Hospital

Barcoding studies discovered two independent sources for blood cells in mice. If confirmed in humans, our understanding of blood cancers, bone marrow transplants, and the aging immune system will change.

The origins of our blood may not be quite what we thought. Using cellular barcoding in mice, groundbreaking research finds that blood cells originate not from one type of mother cell, but two, with potential implications for blood cancers, bone marrow transplant, and immunology. Fernando Camargo, PhD, of the Stem Cell Program at Boston Childrens Hospital led the study, published in the journal Nature on June 15, 2022.

Historically, people have believed that most of our blood comes from a very small number of cells that eventually become blood stem cells, also known as hematopoietic stem cells, says Camargo, who is also a member of the Harvard Stem Cell Institute and a professor at Harvard University. We were surprised to find another group of progenitor cells that do not come from stem cells. They make most of the blood in fetal life until young adulthood, and then gradually start decreasing.

The researchers are now following up to see if the findings also apply to humans. If so, these cells, known as embryonic multipotent progenitor cells (eMPPs), could potentially inform new treatments for boosting aging peoples immune systems. They could also shed new light on blood cancers, especially those in children, and help make bone marrow transplants more effective.

Camargos team applied a barcoding technique they developed several years ago. Using either an enzyme known as transposase or CRISPR gene editing, they inserted unique genetic sequences into embryonic mouse cells in such a way that all the cells descended from them also carried those sequences. This enabled the team to track the emergence of all the different types of blood cells and where they came from, all the way to adulthood.

Previously, people didnt have these tools, says Camargo. Also, the idea that stem cells give rise to all the blood cells was so embedded in the field that no one attempted to question it. By tracking what happened in mice over time, we were able to see new biology.

Through barcoding, the researchers found that eMPPs, as compared with blood stem cells, are a more abundant source of most lymphoid cells important to the immune responses, such as B cells and T cells. Camargo believes the decrease in eMPPs that they observed with age may explain why peoples immunity weakens as they get older.

Were now trying to understand why these cells peter out in middle age, which could potentially allow us to manipulate them with the goal of rejuvenating the immune system, says Camargo.

In theory, there could be two approaches: extending the life of eMPP cells, perhaps through growth factors or immune signaling molecules, or treating blood stem cells with gene therapy or other approaches to make them more like eMPPs.

Camargo is also excited about the potential implications for better understanding and treating blood cancers. For example, myeloid leukemias, striking mostly older people, affect myeloid blood cells such as granulocytes and monocytes. Camargo thinks these leukemias may originate from blood stem cells, and that leukemias in children, which are mostly lymphoid leukemias, may originate from eMPPs.

We are following up to try to understand the consequences of mutations that lead to leukemia by looking at their effects in both blood stem cells and eMPPs in mice, he says. We want to see if the leukemias that arise from these different cells of origin are different lymphoid-like or myeloid-like.

Finally, the recognition that there are two types of mother cells in the blood could revolutionize bone marrow transplant.

When we tried to do bone marrow transplants in mice, we found that the eMPPs didnt engraft well; they only lasted a few weeks, says Camargo. If we could add a few genes to get eMPPs to engraft long term, they could potentially be a better source for a bone marrow transplant. They are more common in younger marrow donors than blood stem cells, and they are primed to produce lymphoid cells, which could lead to better reconstitution of the immune system and fewer infection complications after the graft.

Reference: Lifelong multilineage contribution by embryonic-born blood progenitors by Sachin H. Patel, Constantina Christodoulou, Caleb Weinreb, Qi Yu, Edroaldo Lummertz da Rocha, Brian J. Pepe-Mooney, Sarah Bowling, Li Li, Fernando G. Osorio, George Q. Daley and Fernando D. Camargo, 15 June 2022, Nature. DOI: 10.1038/s41586-022-04804-z

Sachin H. Patel, MD, PhD, of the Stem Cell Program (now at University of California San Francisco) and Constantina Christodoulou, PhD (now at Bristol Myers Squibb) were co-first authors on the paper. The study was funded by the National Institutes of Health (HL128850-01A1, P01HL13147), the Evans MDS Foundation, the Alex Lemonade Foundation, the Leukemia and Lymphoma Society, and the Howard Hughes Medical Institute. The authors declare no competing interests.

Link:
The Origins of Our Blood May Not Be What We Thought - SciTechDaily

The end of Roe v. Wade affects more than just abortion – Vox.com

The end of Roe v. Wade will not only jeopardize access to abortion in many states, it could have wide-ranging and unpredictable consequences for medical care, including fertility treatment, contraception, and cancer care.

This post-Roe world will be, in many ways, a new era for medical care in the United States, one that could transform medical services for conditions that range far beyond pregnancy, either by making them illegal or by putting their legality in question.

The consequences are unpredictable. Michelle Banker, director of reproductive rights and health litigation at the National Womens Law Center, told me in an interview before Fridays decision that the effect on other types of health care will depend upon the answers to open and untested questions in US courts. Some of it will rest on how judges will interpret new state abortion bans. States could also be emboldened by the Supreme Courts ruling to pass new legislation that restricts other medical services.

History would suggest places that outlaw abortion tend to have less access to other reproductive care as well. In Ireland, which only recently legalized abortion, there is still less access to in vitro fertilization and certain contraceptives than in the rest of Europe, even after abortion became legal. In the US, a health system that is already fractured will become even more so, limiting access to medical care particularly for marginalized patients. Whether you can get certain health care services may be predicated on where you live (or whether you can afford to travel).

The breadth of the potential health care consequences is so broad, Banker said. The first place to start is this is going to result in the death of pregnant people.

The United States has the highest maternal mortality rates among wealthy nations; Black Americans have a significantly higher mortality rate than anywhere else in the developed world. The risk of death from carrying a pregnancy to term is much higher than the risk of death from undergoing an abortion. One estimate puts the number of forced birth in the first year after Roe is overturned at 75,000; the maternal mortality rate in the US is about 1 in 10,000.

The impact the end of Roe could have on pregnancy care could reach much further. As the Atlantics Sarah Zhang wrote, pregnant women undergo genetic and other tests throughout their pregnancy, meant to assess the health of the fetus and identify any anomalies that could be fatal or life-altering. In some cases, parents who learn about these anomalies choose abortion. But that may no longer be so simple if abortion is now outlawed or severely limited. Decisions about whether to get genetic testing and when could be affected.

By the same token, most abortion bans would carve out exceptions if the health of the mother were in jeopardy. But whether a complication represents a life-threatening risk to the mothers health is in part a judgment call on the part of her doctor and the possibility of legal consequences could make the cost of mistakes much higher.

At the very least, there may well be a chilling effect due to providers and patients uncertainty as to whether treatment could expose them to civil or criminal liability, Banker said.

Fetal personhood laws that convey constitutional protections to unborn fetuses would further limit a pregnant persons choices in medical care. Several states have attempted to pass such a law, but they have thus far been held up by the courts. This new post-Roe jurisprudence could embolden those states and others to put such measures into place. Law enforcement or private citizens, depending on the state law, could bring complaints. The recently signed Texas law, for example, deputizes private citizens by creating a financial incentive for them to take civil action against people who seek or provide abortions.

Or, in a less extreme example, what happens if a pregnant person is also receiving cancer treatment or taking mental health medication that could affect the health of their fetus? If they stop receiving that medical care, their health could be in danger. But if they continue to receive it, the fetus could be affected. What are they and their doctor supposed to do?

The laws that criminalize abortion are going to impact medical decision-making, and thats terrifying, Banker said.

Supporters of abortion rights fear that, unchained by the Supreme Court, states could push deeper and deeper into the lives of pregnant women and the decisions they make about how to conduct themselves.

People have been arrested for substance use during pregnancy, based on reasoning that they are harming the growth of the pregnancy. Tennessee passed the first law permitting the prosecution of pregnant women who use drugs. That alone is objectionable to people who oppose a criminalized approach to substance use. But they also worry that such laws are just the tip of the iceberg in a post-Roe reality. Could a pregnant woman be charged with a crime if she drinks a glass of wine? Or if she goes on a hiking trip that a complainant thinks would imperil the health of her fetus?

These questions will be answered by the specifics of state laws and the discretion of prosecutors in different places. But they are questions that were unfathomable just a few months ago.

How far down this path could states go? said Elizabeth Nash, who tracks state policy at the Guttmacher Institute, in an interview before Fridays Supreme Court ruling. That might sound a bit far-fetched to people but we have seen states take drastic actions in relation for some pregnant people.

Beyond medical care during pregnancy, the end of Roe could usher in a wave of new restrictions on access to contraception and fertility treatment.

The right to contraception is currently upheld by two previous Supreme Court decisions: Griswold v. Connecticut enshrined the right for married people and Eisenstadt v. Baird did the same for unmarried people.

But the current Court is clearly not bound by those precedents if they are willing to overturn Roe v. Wade. And some prominent Republicans, such as Sen. Marsha Blackburn (R-TN), have referred to those prior court decisions as constitutionally unsound in the days since the Alito draft leaked.

That puts case law in jeopardy because it relies on this idea that rights not specifically named in the Constitution are only entitled to special protection if they are deeply rooted in the nations traditions, Banker said.

Other experts I spoke to agreed. The stage is very much set for state legislators to ban contraception if they want to, Sean Tipton, who works on policy issues at the American Society for Reproductive Medicine, told me before the Supreme Court ruled.

Would state legislators want to ban condoms or even birth control pills? Maybe not. But new laws or even state abortion bans could target other kinds of birth control.

Many of these states want to define the beginning of life as early as possible in the biological process. Oklahoma, for one, passed a law that recognized an unborn childs life as beginning at fertilization. Other states describe the moment of conception. But, as Tipton pointed out, the early stages of pregnancy are, medically speaking, a process. There is not a single moment of conception.

But if states define life in such a way, then contraceptives that could prevent a fertilized egg from becoming implanted could be under threat.

IUDs and the morning-after pill would be threatened under such a legal regime. In the vast majority of cases, IUDs work by preventing fertilization: the sperm and the egg never meet in the first place. But they also might prevent implantation under certain circumstances. There is also some controversy about whether Plan B, the morning-after pill, prevents fertilization in the first place or whether it blocks the implantation of a fertilized egg. The latter could arguably be illegal in states that recognize life at fertilization. Lawmakers in Idaho, for example, announced hearings on whether to ban emergency contraceptives and possibly IUDs before the Supreme Court had even issued its final ruling.

Then there are fertility treatments particularly in vitro fertilization that depend on fostering a larger number of eggs but typically only use a small number of them. If an embryo is conferred the same rights as a toddler, are those procedures suddenly illegal?

As Tipton put it to me, what if a doctor puts 199 embryos in a freezer for IVF treatment, and 198 of them come out of the freezer okay? Does that mean a homicide has been committed? he said.

Experts imagine other possible restrictions on procedures like IVF, particularly in states that define life as beginning at conception or fertilization. That alone could put IVF in legal jeopardy. States could also institute new restrictions on those procedures, now that the right to privacy has been redefined. Maybe the number of embryos could be limited. Maybe state legislators restrict which people are allowed to avail themselves of those services to only straight married couples, for example.

And while there is a tension between ostensibly pro-life politicians restricting access to fertility care, there is an expectation that anti-abortion advocates would be willing to let these medical services be collateral damage in order to achieve the goal of outlawing abortion.

Most right-to-life proponents are not interested in doing anything to hurt fertility patients, Tipton said. But theyre very willing to throw those patients under the bus to end abortion.

The new jurisprudence could also affect access to health care that has nothing to do with pregnancy or reproduction, experts say.

Medical care for people undergoing a gender transition would be one possible casualty. The decision in particular puts gender-affirming care in its crosshairs, Banker said.

In the opinion, Alito cited a 1974 decision, Geduldig v. Aiello, that takes what Banker calls a very narrow and cramped view of what constitutes sex discrimination. For Alitos purposes, that narrow view of sex discrimination supports the argument that banning abortion would not constitute discrimination against pregnant people on the basis of sex.

But Banker says the same logic could be applied to gender-affirming health care such as surgery or hormonal treatments. If the Supreme Courts definition of sex discrimination is now much narrower than it used to be, then opponents of those services could argue that denying a person gender-affirming medical care is not actually discriminatory.

Those arguments are easily refuted under modern precedent, Banker told me. But the drafts language and citation to Geduldig raises concerns that we may see those arguments gain more traction.

Old battles over medical research or treatment could also resurface, Tipton said. Modern science has developed treatments for spinal cord injuries, myelofibrosis, and even certain cancers by relying on stem cells. More treatments are in clinical trials right now. But their prospects could be compromised if access to those materials is limited. Some stem cells are collected from adult body tissue, but others come from embryos.

Much of this will depend on how aggressive anti-abortion advocates decide to be, and on the success of abortion rights advocates in mounting a political and legal response to a ruling overturning Roe.

But it will undoubtedly be a new era for health care in the United States, with potentially devastating consequences for patients with a wide array of medical needs.

Read more:
The end of Roe v. Wade affects more than just abortion - Vox.com

Global Regenerative Medicines: Bone and Joint Applications Market Forecast to 2027: Rising Number of Bone and Joint Disorders and Orthopedic Surgeries…

DUBLIN--(BUSINESS WIRE)--The "Regenerative Medicines: Bone and Joint Applications" report has been added to ResearchAndMarkets.com's offering.

Report Includes

Reasons for Doing This Study:

The purpose of this report is to provide a summary of regenerative medicine products for the treatment of diseases and disorders of the bones and joints. Regenerative therapies have the potential to progress medical outcomes, improve quality of life and decrease overall healthcare costs.

A major objective is the utilization of living cells to repair or replace body tissue damaged by injury, disorder or the ageing process. The most successful products draw upon multidisciplinary fields such as biology, medicine, engineering and, particularly, biomedical engineering.

This report is designed to be a critical decision-making tool for the intended audience, which includes biopharmaceutical market players, potential market entrants and other professionals involved with or interested in cell and gene therapy and regenerative therapy in orthopedic sector.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Chapter 4 Impact of Covid-19

Chapter 5 Market Dynamics

Chapter 6 Market Breakdown by Technology

Chapter 7 Market Breakdown by Application

Chapter 8 Market Breakdown by Region

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/yqof9i

Read more from the original source:
Global Regenerative Medicines: Bone and Joint Applications Market Forecast to 2027: Rising Number of Bone and Joint Disorders and Orthopedic Surgeries...

The stem cell assays market is projected to reach USD 4.5 Billion by 2027 from USD 1.9 Billion in 2022, at a CAGR of 17.7% – Yahoo Finance

ReportLinker

during the forecast period. The growth of the market is projected to be driven by collaborations and agreements among market players for stem cell assay products & services, launch of new stem cell analysis systems such as flow cytometers and increase in R&D expenditure by biopharmaceutical and biotechnology companies.

New York, June 28, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Stem Cell Assays Market by Type, Cell Type, Product & Service, Application, End User - Global Forecast to 2027" - https://www.reportlinker.com/p04221306/?utm_source=GNW

The viability/cytotoxicity assays accounted for the largest share of the type segment in the stem cell assays market in 2021. Cell viability assays help to determine the number of live and dead cells in a culture medium.The viability/cytotoxicity assays includes various types such as tetrazolium reduction assays, resazurin cell viability assays, calcein-AM cell viability assays, and other viability/cytotoxicity assays.

The cell viability/cytotoxicity market is likely to be driven by rise R&D spending on stem cell research, increase in demand for stem cell assays in drug discovery and development of new stem cell therapies..

The adult stem cells segment accounted for the largest share of the cell type segment in the stem cell assays market in 2021. The adult stem cells account for the largest share of the stem cell assays market.The adult stem cells include mesenchymal stem cells, induced pluripotent stem cells, hematopoietic stem cells, umbilical cord stem cells, and neural stem cells.

The growth of adult stems cells segment is driven by increasing usage of adult stem cells in regenerative medicine and development of advanced therapies. Key players in the stem cell assays market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Danaher (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), PerkinElmer (US), Agilent Technologies (US), Promega Corporation (US), Cell Biolabs (US), Miltenyi Biotec (Germany), STEMCELL Technologies (Canada), Bio-Techne Corporation (US), FUJIFILM Holdings Corporation (Japan), Charles River Laboratories (US), HemoGenix Inc. (US), Lonza Group (Switzerland), Takara Bio Inc. (Japan), Creative Bioarray (US), AAT Bioquest, Inc. (US), BPS Bioscience, Inc. (US), Enzo Biochem (US), PromoCell GmbH (Germany), Biotium (US), Geno Technology (US), Abcam plc (UK), and ReachBio Research Labs (US).

Asia Pacific: The fastest-growing region in the stem cell assays market The Asia Pacific is estimated to be the fastest-growing segment of the market, owing to rising prevalence of cancer & other diseases, increasing R&D spending on biopharmaceutical projects and focus on developing stem cell based therapies. In this region, China and Japan are the largest markets.

The primary interviews conducted for this report can be categorized as follows: By Respondent: Supply Side- 80% and Demand Side - 20% By Designation: Managers- 45%, CXOs and Director level - 30%, and Executives - 25% By Region: North America -20%, Europe -10%, Asia-Pacific -55%, RoW -15%

List of Companies Profiled in the Report: Thermo Fisher Scientific Inc. (US) Merck KGaA (Germany) Danaher (US) Becton, Dickinson and Company (US) Bio-Rad Laboratories (US) PerkinElmer (US) Agilent Technologies (US) Promega Corporation (US) Cell Biolabs (US) Miltenyi Biotec (Germany) STEMCELL Technologies (Canada) Bio-Techne Corporation (US) FUJIFILM Holdings Corporation (Japan) Charles River Laboratories (US) HemoGenix Inc. (US) Lonza Group (Switzerland) Takara Bio Inc. (Japan) Creative Bioarray (US) AAT Bioquest, Inc. (US) BPS Bioscience, Inc. (US) Enzo Biochem (US) PromoCell GmbH (Germany) Biotium (US) Geno Technology (US) Abcam plc (UK) ReachBio Research Labs (US).

Research Coverage: This report provides a detailed picture of the stem cell assays market.It aims at estimating the size and future growth potential of the market across different segments such as the product, functionality, formulation and region.

The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell assays market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.

This report will enable stakeholders to understand the markets pulse and provide them with information on the key market drivers, restraints, challenges, trends, and opportunities. Read the full report: https://www.reportlinker.com/p04221306/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Read the original here:
The stem cell assays market is projected to reach USD 4.5 Billion by 2027 from USD 1.9 Billion in 2022, at a CAGR of 17.7% - Yahoo Finance

Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutical for Off-the-Shelf, iPSC-derived CAR NK and CAR T-Cell…

Fate Therapeutics, Inc.

ONO to Contribute Novel Binding Domains for a Second Solid Tumor Antigen to the Collaboration

Expanded Partnership Enables Development of both CAR NK and CAR T-cell Collaboration Candidates for Solid Tumors

SAN DIEGO, June 28, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that it has expanded its off-the-shelf, iPSC-derived, cell-based cancer immunotherapy collaboration with ONO Pharmaceutical Co., Ltd. (ONO) to include the development of chimeric antigen receptor (CAR) NK cell collaboration candidates. In addition, as part of the collaborations expansion, ONO will contribute novel binding domains targeting a second solid tumor antigen. Under the original Collaboration and Option Agreement entered into between Fate and ONO in September 2018, ONO has contributed novel binding domains targeting an initial solid tumor antigen, and Fate is currently conducting preclinical development of a multiplexed-engineered, iPSC-derived CAR T-cell product candidate for solid tumors.

Our collaboration with ONO has focused on driving innovation in the field of cell therapy for solid tumors, and we are excited by the preclinical data we have observed with our first iPSC-derived CAR T-cell product candidate, said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. We are impressed with the differentiated antigen binders that ONO has contributed to the partnership, and we are pleased to expand our collaboration to initiate preclinical development of collaboration products targeting a second solid tumor antigen.

Under the terms of the amended Collaboration and Option Agreement, Fate will advance iPSC-derived CAR NK and CAR T-cell product candidates to a pre-defined preclinical milestone, at which point ONO has an option to assume responsibility for worldwide development and commercialization with Fate retaining the right to jointly develop and commercialize in the United States and Europe. Fate retains all rights of manufacture of collaboration products on a global basis.

Story continues

The first multiplexed-engineered, iPSC-derived CAR T-cell product candidate under our collaboration with Fate Therapeutics incorporates multiple mechanisms of action designed to specifically address solid tumors and is successfully advancing toward clinical development, said Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research of ONO. Based on the collaboration progress and Fates proven ability to develop innovative product candidates, we are excited to expand our collaboration to include a second solid tumor target and to continue our work with Fate in developing first-in-class, off-the-shelf CAR NK and CAR T-cell therapies for cancer patients.

Fate will continue to receive committed research funding from ONO during the preclinical option period, and is eligible to receive a preclinical option exercise fee as well as clinical, regulatory and commercialization milestone payments from ONO in connection with the development and commercialization of each product candidate. In addition, Fate is eligible to receive tiered royalties on net sales by ONO of each product candidate in the ONO territory.

About Fate Therapeutics iPSC Product Platform The Companys proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that are designed to be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Companys first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Companys platform is uniquely designed to overcome numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications.

About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Companys immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit http://www.fatetherapeutics.com.

Fate Therapeutics Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the impact, timing, conduct and the potential benefits of the collaboration, including expected funding and payments to be received by Fate Therapeutics under the collaboration, as well as the capabilities, expertise and responsibilities of each of Fate Therapeutics and ONO Pharmaceutical. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with: the success, cost and timing of product development activities under the collaboration; the ability of Fate Therapeutics and ONO Pharmaceutical to obtain regulatory approval for and to commercialize any product candidates developed under the collaboration; regulatory requirements and regulatory developments; the success of competing treatments and technologies; the risk of cessation or delay of any development activities under the collaboration for a variety of reasons; any adverse effects or events, or other negative results, that may be observed in preclinical or clinical development of any product candidates developed through the collaboration; and the risk that funding and payments received by Fate Therapeutics under the collaboration may be less than expected. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Fate Therapeutics actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in Fate Therapeutics periodic filings with the Securities and Exchange Commission, including but not limited to Fate Therapeutics most recently filed periodic report, and from time to time in Fate Therapeutics press releases and other investor communications.Fate Therapeutics is providing the information in this release as of this date and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 christina@sternir.com

Go here to read the rest:
Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutical for Off-the-Shelf, iPSC-derived CAR NK and CAR T-Cell...